69 reports of this reaction
8.9% of all ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE reports
#1 most reported adverse reaction
BREAST CANCER FEMALE is the #1 most commonly reported adverse reaction for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, manufactured by Method Pharmaceuticals. There are 69 FDA adverse event reports linking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE to BREAST CANCER FEMALE. This represents approximately 8.9% of all 778 adverse event reports for this drug.
Patients taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is moderately reported among ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE users, representing a notable but not dominant share of adverse events.
In addition to breast cancer female, the following adverse reactions have been reported for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 69 FDA reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 8.9% of all adverse event reports for ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, making it one of the most commonly reported side effect.
If you experience breast cancer female while taking ESTERIFIED ESTROGENS AND METHYLTESTOSTERONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.